Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galsome-NEO
- Development stage
- Unknown
- Lead developer
- Ghent University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Galsome-NEO** is an investigational, personalized neoantigen-targeted cancer vaccine comprising neoepitope-encoding mRNA formulated in lipid nanoparticles and adjuvanted with the glycolipid alpha-galactosylceramide. The mRNA is intended to drive presentation of patient-specific tumor neoantigens and induce antitumor T-cell responses, while alpha-galactosylceramide activates invariant natural killer T cells through CD1d-mediated presentation. It is being developed at Ghent University and Ghent University Hospital for locally advanced unresectable PD-L1-negative non-small cell lung cancer. ([research.ugent.be](https://research.ugent.be/web/result/project/0a4d837b-9672-4a06-ab4b-0e55b80a19c1/details/en))
02
Targets
Tumor-specific neoantigen–MHC class I complexInvariant natural killer T-cell receptor–CD1d–alpha-galactosylceramide complexCD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on Galsome-NEO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galsome-NEO.